Carcinoma of unknown primary - An orphan disease?

Breast Care

Volumn 3, Issue 3, 2008, Pages 164-170

  Krämer, Alwin ^a   Hübner, Gerdt ^b   Schneeweiss, Andreas ^a   Folprecht, Gunnar ^c   Neben, Kai ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b SANA KLINIKUM OFFENBACH   (Germany)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Carcinoma of unknown primary; Cetuximab; CUP; Metastases

Indexed keywords

ALPHA FETOPROTEIN; ANTINEOPLASTIC AGENT; BLEOMYCIN; CA 125 ANTIGEN; CA 15-3 ANTIGEN; CA 19-9 ANTIGEN; CALCITONIN; CARBOPLATIN; CARCINOEMBRYONIC ANTIGEN; CETUXIMAB; CHORIONIC GONADOTROPIN BETA SUBUNIT; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; METHOTREXATE; MITOMYCIN C; NAVELBINE; PACLITAXEL; PLATINUM DERIVATIVE; PROSTATE SPECIFIC ANTIGEN; TAXANE DERIVATIVE; TUMOR MARKER;

AXILLARY LYMPH NODE; BREAST TUMOR; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER OF UNKNOWN PRIMARY SITE; CANCER SURVIVAL; CARCINOMATOUS PERITONITIS; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DRUG EFFICACY; DRUG TARGETING; GENE EXPRESSION; HUMAN; INGUINAL LYMPH NODE; LYMPH NODE METASTASIS; METASTASIS; MONOTHERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCULT CANCER; ONCOGENE NEU; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SQUAMOUS CELL CARCINOMA;

EID: 46949093114     PISSN: 16613791     EISSN: 16613805     Source Type: Journal    
DOI: 10.1159/000136001     Document Type: Review

References (68)

1. Abbruzzese JL, Abbruzzese MC, Lenzi R, Hess KR, Raber MN: Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin. J Clin Oncol 1995;13:2094-2103.
2. Eagan RT, Therneau TM, Rubin J, Long HJ, Schutt AJ: Lack of value for cisplatin added to mitomycin-doxorubicin combination chemotherapy for carcinoma of unknown primary site. A randomized trial. Am J Clin Oncol 1987;10:82-85.
3. Goldberg RM, Smith FP, Ueno W, Ahlgren JD, Schein PS: 5-fluorouracil, adriamycin, and mitomycin in the treatment of adenocarcinoma of unknown primary. J Clin Oncol 1986;4:395-399.
4. Greco FA, Burris HA 3rd, Erland JB, Gray JR, Kalman LA, Schreeder MT, Hainsworth JD: Carcinoma of unknown primary site. Cancer 2000;89:2655-2660.
5. Greco FA, Gray J, Burris HA 3rd, Erland JB, Morrissey LH, Hainsworth JD: Taxane-based chemotherapy for patients with carcinoma of unknown primary site. Cancer J 2001;7:203-212.
6. Altman E, Cadman E: An analysis of 1539 patients with cancer of unknown primary site. Cancer 1986;57:120-124.
7. Hess KR, Abbruzzese MC, Lenzi R, Raber MN, Abbruzzese JL: Classification and regression tree analysis of 1000 consecutive patients with unknown primary carcinoma. Clin Cancer Res 1999;5:3403-3410.
8. Le Chevalier T, Cvitkovic E, Caille P, Harvey J, Contesso G, Spielmann M, Rouesse J: Early metastatic cancer of unknown primary origin at presentation. A clinical study of 302 consecutive autopsied patients. Arch Internal Med 1988;148:2035-2039.
9. Van de Wouw AJ, Janssen-Heijnen ML, Coebergh JW, Hillen HF: Epidemiology of unknown primary tumours; incidence and population-based survival of 1285 patients in Southeast Netherlands, 1984-1992. Eur J Cancer 2002;38:409-413.
10. Hainsworth JD, Spigel DR, Litchy S, Greco FA: Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network Study. J Clin Oncol 2006;24:3548-3554.
11. Didolkar MS, Fanous N, Elias EG, Moore RH: Metastatic carcinomas from occult primary tumors. A study of 254 patients. Ann Surg 1977;186:625-630.
12. Hainsworth JD, Johnson DH, Greco FA: Poorly differentiated neuroendocrine carcinoma of unknown primary site. A newly recognized clinicopathologic entity. Ann Internal Med 1988;109:364-371.
13. Nystrom JS, Weiner JM, Heffelfinger-Juttner J, Irwin LE, Bateman JR, Wolf RM: Metastatic and histologic presentations in unknown primary cancer. Sem Oncol 1977;4:53-58.
14. Culine S, Kramar A, Saghatchian M, Bugat R, Lesimple T, Lortholary A, Merrouche Y, Laplanche A, Fizazi K: Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site. J Clin Oncol 2002;20:4679-4683.
15. Van de Wouw AJ, Jansen RL, Griffioen AW, Hillen HF: Clinical and immunohistochemical analysis of patients with unknown primary tumour. A search for prognostic factors in UPT. Anticancer Res 2004;24:297-301.
16. Mayordomo JI, Guerra JM, Guijarro C, Garcia-Prats MD, Gomez A, Lopez-Brea M, Gonzalez R, Hergueta P, Lopez-Pino MA, Martinez-Tello F, et al.: Neoplasms of unknown primary site: a clinicopathological study of autopsied patients. Tumori 1993;79:321-324.
17. Kaufmann O, Fietze E, Dietel M: Immunohistochemical diagnosis in cancer metastasis of unknown primary tumor. Pathologe 2002;23:183-197.
18. Voigt JJ, Mathieu MC, Bibeau F: The advent of immunohistochemistry in carcinoma of unknown primary site: a major progress; in Fizazi K (ed): Carcinoma of an Unknown Primary Site. New York, Taylor and Francis, 2006, pp. 25-35.
19. Bugat R, Bataillard A, Lesimple T, Voigt JJ, Culine S, Lortholary A, Merrouche Y, Ganem G, Kaminsky MC, Negrier S, Perol M, Laforet C, Bedossa P, Bertrand G, Coindre JM, Fizazi K: Summary of the standards, options and recommendations for the management of patients with carcinoma of unknown primary site (2002). Brit J Cancer 2003;89:S59-66.
20. Seve P, Billotey C, Broussolle C, Dumontet C, Mackey JR: The role of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography in disseminated carcinoma of unknown primary site. Cancer 2007;109:292-299.
21. Bohuslavizki KH, Klutmann S, Kroger S, Sonnemann U, Buchert R, Werner JA, Mester J, Clausen M: FDG PET detection of unknown primary tumors. J Nucl Med 2000;41:816-822.
22. Regelink G, Brouwer J, de Bree R, Pruim J, van der Laan BF, Vaalburg W, Hoekstra OS, Comans EF, Vissink A, Leemans CR, Roodenburg JL: Detection of unknown primary tumours and distant metastases in patients with cervical metastases: value of FDG-PET versus conventional modalities. Eur J Nucl Med Mol Imag 2002;29:1024-1030.
23. Fizazi K: Carcinoma of an Unknown Primary Site. New York, Taylor and Francis, 2006.
24. Guarischi A, Keane TJ, Elhakim T: Metastatic inguinal nodes from an unknown primary neoplasm. A review of 56 cases. Cancer 1987;59:572-577.
25. Bhatia SK, Saclarides TJ, Witt TR, Bonomi PD, Anderson KM, Economou SG: Hormone receptor studies in axillary metastases from occult breast cancers. Cancer 1987;59:1170-1172.
26. Schorn C, Fischer U, Luftner-Nagel S, Westerhof JP, Grabbe E: MRI of the breast in patients with metastatic disease of unknown primary. Eur Radiol 1999;9:470-473.
27. Block EF, Meyer MA: Positron emission tomography in diagnosis of occult adenocarcinoma of the breast. Am Surgeon 1998;64:906-908.
28. Kole AC, Nieweg OE, Pruim J, Hoekstra HJ, Koops HS, Roodenburg JL, Vaalburg W, Vermey A: Detection of unknown occult primary tumors using positron emission tomography. Cancer 1998;82:1160-1166.
29. Jackson B, Scott-Conner C, Moulder J: Axillary metastasis from occult breast carcinoma: diagnosis and management. Am Surgeon 1995;61:431-434.
30. Rosen PP, Kimmel M: Occult breast carcinoma presenting with axillary lymph node metastases: a follow-up study of 48 patients. Hum Pathol 1990;21:518-523.
31. Van Ooijen B, Bontenbal M, Henzen-Logmans SC, Koper PC: Axillary nodal metastases from an occult primary consistent with breast carcinoma. Brit J Surg 1993;80:1299-1300.
32. Vlastos G, Jean ME, Mirza AN, Mirza NQ, Kuerer HM, Ames FC, Hunt KK, Ross MI, Buchholz TA, Buzdar AU, Singletary SE: Feasibility of breast preservation in the treatment of occult primary carcinoma presenting with axillary metastases. Ann Surg Oncol 2001;8:425-431.
33. Merson M, Andreola S, Galimberti V, Bufalino R, Marchini S, Veronesi U: Breast carcinoma presenting as axillary metastases without evidence of a primary tumor. Cancer 1992;70:504-508.
34. Campana F, Fourquet A, Ashby MA, Sastre X, Jullien D, Schlienger P, Labib A, Vilcoq JR: Presentation of axillary lymphadenopathy without detectable breast primary (T0 N1b breast cancer): experience at Institut Curie. Radiotherapy Oncol 1989;15:321-325.
35. Vilcoq JR, Calle R, Ferme F, Veith F: Conservative treatment of axillary adenopathy due to probable subclinical breast cancer. Arch Surg 1982;117:1136-1138.
36. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Eng J Med 1996;334:1-6.
37. Abbruzzese JL, Abbruzzese MC, Hess KR, Raber MN, Lenzi R, Frost P: Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients. J Clin Oncol 1994;12:1272-1280.
38. Pavlidis N, Briasoulis E, Hainsworth J, Greco FA: Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer 2003;39:1990-2005.
39. Hübner G, Wildfang I, Schmoll HJ: CUP, in Schmoll HJ (ed): Kompendium Internistische Onkologie, Band 2. Berlin, Springer, 1999, pp. 2137-2181.
40. Rades D, Kuhnel G, Wildfang I, Borner AR, Schmoll HJ, Knapp W: Localised disease in cancer of unknown primary (CUP): the value of positron emission tomography (PET) for individual therapeutic management. Ann Oncol 2001;12:1605-1609.
41. Nguyen LN, Maor MH, Oswald MJ: Brain metastases as the only manifestation of an undetected primary tumor. Cancer 1998;83:2181-2184.
42. Salvati M, Cervoni L, Raco A: Single brain metastases from unknown primary malignancies in CTera. J Neuro Oncol 1995;23:75-80.
43. Hainsworth JD, Erland JB, Kalman LA, Schreeder MT, Greco FA: Carcinoma of unknown primary site: treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide. J Clin Oncol 1997;15:2385-2393.
44. Greco FA, Erland JB, Morrissey LH, Burris HA, 3rd, Hermann RC, Steis R, Thompson D, Gray J, Hainsworth JD: Carcinoma of unknown primary site: phase II trials with docetaxel plus cisplatin or carboplatin. Ann Oncol 2000;11:211-215.
45. Greco FA, Burris HA 3rd, Litchy S, Barton JH, Bradof JE, Richards P, Scullin DC, Jr., Erland JB, Morrissey LH, Hainsworth JD: Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: a Minnie Pearl Cancer Research Network study. J Clin Oncol 2002;20:1651-1656.
46. Greco FA, Hainsworth JD, Yardley DA: Sequential paclitaxel/carboplatin/ etoposide followed by irinotecan/gemcitabine for patients with carcinoma of unknown primary site: a Minnie Pearl Cancer Research Network phase II trial. Proc Am Soc Clin Oncol 2002;21:161a.
47. Holmes FF, Fouts TL: Metastatic cancer of unknown primary site. Cancer 1970;26:816-820.
48. Krementz ET, Cerise EJ, Foster DS, Morgan LR Jr: Metastases of undetermined source. Curr Problems Cancer 1979;4:4-37.
49. Markman M: Metastatic adenocarcinoma of unknown primary site: analysis of 245 patients seen at The Johns Hopkins Hospital from 1965-1979. Med Pediat Oncol 1982;10:569-574.
50. Moertel CG, Reitemeier RJ, Schutt AJ, Hahn RG: Treatment of the patient with adenocarcinoma of unknown origin. Cancer 1972;30:1469-1472.
51. Levi F, Te VC, Erler G, Randimbison L, La Vecchia C: Epidemiology of unknown primary tumours. Eur J Cancer 2002;38:1810-1812.
52. Muir C: Cancer of unknown primary site. Cancer 1995;75:353-356.
53. Palmeri S, Lorusso V, Palmeri L, Vaglica M, Porta C, Nortilli R, Ferrau F, Comella G, Massidda B, Danova M: Cisplatin and gemcitabine with either vinorelbine or paclitaxel in the treatment of carcinomas of unknown primary site : results of an Italian multicenter, randomized, phase II study. Cancer 2006;107:2898-2905.
54. Culine S, Lortholary A, Voigt JJ, Bugat R, Theodore C, Priou F, Kaminsky MC, Lesimple T, Pivot X, Coudert B, Douillard JY, Merrouche Y, Allouache J, Goupil A, Negrier S, Viala J, Petrow P, Bouzy J, Laplanche A, Fizazi K: Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01). J Clin Oncol 2003;21:3479-3482.
55. Assersohn L, Norman AR, Cunningham D, Iveson T, Seymour M, Hickish T, Massey A, Prior Y, Hill ME: A randomised study of protracted venous infusion of 5-fluorouracil (5-FU) with or without bolus mitomycin C (MMC) in patients with carcinoma of unknown primary. Eur J Cancer 2003;39:1121-1128.
56. Dowell JE, Garrett AM, Shyr Y, Johnson DH, Hande KR: A randomized Phase II trial in patients with carcinoma of an unknown primary site. Cancer 2001;91:592-597.
57. Falkson CI, Cohen GL: Mitomycin C, epirubicin and cisplatin versus mitomycin C alone as therapy for carcinoma of unknown primary origin. Oncol 1998;55:116-121.
58. Milliken ST, Tattersall MH, Woods RL, Coates AS, Levi JA, Fox RM, Raghavan D: Metastatic adenocarcinoma of unknown primary site. A randomized study of two combination chemotherapy regimens. Eur J Cancer Clin Oncol 1987;23:1645-1648.
59. Woods RL, Fox RM, Tattersall MH, Levi JA, Brodie GN: Metastatic adenocarcinomas of unknown primary site: a randomized study of two combination-chemotherapy regimens. N Eng J Med 1980;303:87-89.
60. Huebner G, Steinbach S, Kohne CH, Stahl M, Kretzschmar A, Eimermacher A, Link H on behalf of the Germann CUP Study Group: Paclitaxel (P)/carboplatin (C) versus gemcitabine (G)/vinorelbine (V) in patients with adeno- or undifferentiated carcinoma of unknown primary (CUP) - a randomized prospective phase-II-trial. Proc Am Soc Clin Oncol 2005;23:330s.
61. Hainsworth JD, Burris HA 3rd, Calvert SW, Willcutt NT, Scullin DC Jr, Bramham J, Greco FA: Gemcitabine in the second-line therapy of patients with carcinoma of unknown primary site: a phase II trial of the Minnie Pearl Cancer Research Network. Cancer Invest 2001;19:335-339.
62. Hainsworth JD, Spigel DR, Raefsky EL, Kuzur ME, Yost K, Kommor M, Litchy S, Greco FA: Combination chemotherapy with gemcitabine and irinotecan in patients with previously treated carcinoma of an unknown primary site: a Minnie Pearl Cancer Research Network Phase II trial. Cancer 2005;104:1992-1997.
63. Massard C, Voigt JJ, Laplanche A, Culine S, Lortholary A, Bugat R, Theodore C, Priou F, Kaminsky MC, Lesimple T, Pivot X, Coudert B, Douillard JY, Merrouche Y, Fizazi K: Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy? Brit J Cancer 2007;97:857-861.
64. Hainsworth JD, Spigel DR, Farley C, Thompson DS, Shipley DL, Greco FA: Phase II trial of bevacizumab and erlotinib in carcinomas of unknown primary site: the Minnie Pearl Cancer Research Network. J Clin Oncol 2007;25:1747-1752.
65. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Eng J Med 2004;351:337-345.
66. Vermorken JB, Trigo J, Hitt R, Koralewski P, Diaz-Rubio E, Rolland F, Knecht R, Amellal N, Schueler A, Baselga J: Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 2007;25:2171-2177.
67. Giaccone G: Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer. J Clin Oncol 2005;23:3235-3242.
68. Morgensztern D, Govindan R: Is there a role for cetuximab in non small cell lung cancer? Clin Cancer Res 2007;13:s4602-4605.